CD30-positive malignant lymphomas: time for a change of management?

被引：5
|
作者：
Engert, Andreas [1 ,2 ]
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp Cologne, GHSG, Cologne, Germany
来源：
HAEMATOLOGICA | 2013年 / 98卷 / 08期
关键词：
BRENTUXIMAB VEDOTIN SGN-35; STERNBERG-REED CELLS; HODGKINS LYMPHOMA; DISEASE; POTENT;
D O I：
10.3324/haematol.2013.091561
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1165 / 1168
页数：5
相关论文
共 50 条
  • [21] HODGKINS-DISEASE AND CD30-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMAS - A CONTINUOUS-SPECTRUM OF MALIGNANT DISORDERS - A QUANTITATIVE MORPHOMETRIC AND IMMUNOHISTOLOGIC STUDY
    LEONCINI, L
    DELVECCHIO, MT
    KRAFT, R
    MEGHA, T
    BARBINI, P
    CEVENINI, G
    POGGI, S
    PILERI, S
    TOSI, P
    COTTIER, H
    AMERICAN JOURNAL OF PATHOLOGY, 1990, 137 (05): : 1047 - 1057
  • [22] Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models
    Gong, Jianhua
    Guo, Feihu
    Cheng, Weihua
    Fan, Hongqiang
    Miao, Qingfang
    Yang, Jigang
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2020, 48 (01) : 408 - 414
  • [23] Unusual Case of CD30-positive Lymphoma with Coexpression of CD 20
    Paetzold, U.
    Wessbecher, R.
    Thoelken, K.
    Zick, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 60 - 61
  • [24] Novel Marker IRF8 Helps Differentiate Between CD30-Positive Large Cell Lymphomas
    McQuaid, Daniel
    Katz, Sam
    Xu, Mina
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 988 - 989
  • [25] CD30-positive cutaneous large cell lymphomas - A comparative study of clinicopathologic and molecular features of 16 cases
    Macgrogan, G
    Vergier, B
    Dubus, P
    BeylotBarry, M
    Belleannee, G
    Delaunay, MM
    Eghbali, H
    Beylot, C
    Rivel, J
    Trojani, M
    Vital, C
    DeMascarel, A
    Bloch, B
    Merlio, JP
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1996, 105 (04) : 440 - 450
  • [26] Novel Marker IRF8 Helps Differentiate Between CD30-Positive Large Cell Lymphomas
    McQuaid, Daniel
    Katz, Sam
    Xu, Mina
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 988 - 989
  • [27] The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas
    Alonso, Ines Garces de los Fayos
    Liang, Huan-Chang
    Turner, Suzanne D.
    Lagger, Sabine
    Merkel, Olaf
    Kenner, Lukas
    CANCERS, 2018, 10 (04)
  • [28] Mucosal CD30-positive T-cell lymphoproliferations arising in the patient with cutaneous CD30-positive T-cell lymphoproliferative disorders
    Habe, K.
    Yamamoto, S.
    Noda, E.
    Ishinaga, H.
    Ohshima, K.
    Yamanaka, K.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S46 - S46
  • [29] Clinical-pathological Classification of CD30-positive Papules
    Koester, F.
    Sheikh, L.
    Siemann-Harms, U.
    Booken, N.
    Schneider, S. W.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 4 - 4
  • [30] Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
    Lesley J. Scott
    Drugs, 2017, 77 : 435 - 445
12345